U.S. Markets close in 4 hrs 57 mins

Featured Company News - iBio Announces Large-Scale Manufacturing Collaboration with Aethlon Medical

LONDON, UK / ACCESSWIRE / October 18, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for iBio, Inc. (NYSE: IBIO), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=IBIO. The Company announced on October 16, 2017, the establishment of an agreement with Aethlon Medical, Inc. (NASDAQ: AEMD) to support a potential large-scale production of the Aethlon Hemopurifier® blood purification device. For immediate access to our complimentary reports, including today's coverage, register for free now at:

http://protraderdaily.com/register/

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on IBIO and AEMD. Go directly to your stock of interest and access today's free coverage at:

http://protraderdaily.com/optin/?symbol=IBIO

http://protraderdaily.com/optin/?symbol=AEMD

The Aethlon Hemopurifier®

The Aethlon Hemopurifier® is a first-in-class therapeutic device designed for the treatment of life-threatening viral infections which cannot be addressed with an approved treatment. On September 12, 2017, Aethlon received an FDA Expedited Access Pathway (EAP) Designation for its Hemopurifier® device, a single-use cartridge that can capture a broad spectrum of highly glycosylated viruses including influenza and hemorrhagic fevers, such as Ebola virus, to reduce viral load in the circulatory system.

The FDA established the EAP program to facilitate rapid patient access to breakthrough technologies which has a potential to address life-threatening disease conditions for which no approved or cleared treatment alternatives exist.

Aethlon, working in collaboration with leading government and non-government research institutes, has validated the ability of the Hemopurifier® to capture a broad-spectrum of pandemic influenza viruses, mosquito-borne viruses, and deadly hemorrhagic viruses. Based on its use to treat Ebola virus, the Hemopurifier® was named a "Top 25 Invention" and one of the "Eleven Most Remarkable Advances in Healthcare," by TIME Magazine in 2014.

The Aethlon/iBio Collaboration

Aethlon/iBio stated that they have collaborated in order to advance large-scale production of a proprietary recombinant form of Galanthus Nivalis Agglutinin (GNA). The GNA produced with iBio's plant-based technology can be immobilized within the Hemopurifier® to bind infectious enveloped viruses. Researchers from the two companies has earlier conducted a feasibility study to produce and screen a panel of recombinantly produced lectin isoforms, which can improve binding capacity and reduce the reliance on less effective extracted mixtures.

Jim Joyce, Chairman and CEO of Aethlon, stated:

"The production of recombinant GNA in iBio's large-scale manufacturing facilities establishes a pathway for us to access a consistent, high quality supply that can support our long-term clinical and commercialization objectives."

Sponsored by Department of Defense

iBio's CDMO facilities were initially designed and constructed under sponsorship of the Defense Advanced Research Projects Agency (DARPA) of the US Department of Defense. These facilities have the capacity to initiate a rapid production response to an infectious disease outbreak or a bioterror attack and to manufacture large quantities of recombinant proteins under Current Good Manufacturing Practices (cGMP') of the US Food and Drug Administration.

About iBio, Inc.

iBio provides a range of product and process development, analytical, and manufacturing services at the large-scale development and manufacturing facility of its subsidiary iBio CDMO, LLC., located in Bryan, Texas. The facility houses laboratory and pilot-scale operations as well as large-scale automated hydroponic systems capable of growing over four million plants as "in process inventory" and delivering over 300 kilograms of therapeutic protein pharmaceutical active ingredient per year.

Last Close Stock Review

On Tuesday, October 17, 2017, the stock closed the trading session at $0.32, advancing 2.79% from its previous closing price of $0.31. A total volume of 628.47 thousand shares have exchanged hands. iBio's stock currently has a market cap of $30.01 million.

On Tuesday, October 17, 2017, Aethlon Medical's stock closed the trading session at $0.97, declining 2.02% from its previous closing price of $0.99. A total volume of 607.30 thousand shares were exchanged during the session, which was above the 3-month average volume of 479.64 thousand shares. The stock currently has a market cap of $14.50 million.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily